These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 12408530)
1. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin. Carlsson T; Weiland O; Reichard O Scand J Gastroenterol; 2002 Oct; 37(10):1228-34. PubMed ID: 12408530 [TBL] [Abstract][Full Text] [Related]
2. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591 [TBL] [Abstract][Full Text] [Related]
3. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C. Buti M; Olive G; Stalgis C; Esteban R; Guardi J Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235 [TBL] [Abstract][Full Text] [Related]
4. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715 [TBL] [Abstract][Full Text] [Related]
5. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041 [TBL] [Abstract][Full Text] [Related]
6. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load. Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622 [TBL] [Abstract][Full Text] [Related]
7. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042 [TBL] [Abstract][Full Text] [Related]
9. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284 [TBL] [Abstract][Full Text] [Related]
10. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. Rivero-Juárez A; Camacho Espejo A; Perez-Camacho I; Neukam K; Caruz A; Mira JA; Mesa P; García-Lázaro M; Torre-Cisneros J; Pineda JA; Rivero A J Antimicrob Chemother; 2012 Jan; 67(1):202-5. PubMed ID: 21990051 [TBL] [Abstract][Full Text] [Related]
11. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Manns M; Reesink H; Berg T; Dusheiko G; Flisiak R; Marcellin P; Moreno C; Lenz O; Meyvisch P; Peeters M; Sekar V; Simmen K; Verloes R Antivir Ther; 2011; 16(7):1021-33. PubMed ID: 22024518 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Reau N; Satoskar R; Te H; DeVoss A; Elsen C; Reddy G; Mohanty S; Jensen D Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395 [TBL] [Abstract][Full Text] [Related]
13. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group. Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200 [TBL] [Abstract][Full Text] [Related]
14. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C. Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S Digestion; 2000; 61(2):90-7. PubMed ID: 10705172 [TBL] [Abstract][Full Text] [Related]
15. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Steindl-Munda P; Ferenci P; Brunner H; Nachbaur K; Datz C; Gschwantler M; Hofer H; Stauber R; Hackl F; Jessner W; Rosenbeiger M; Gangl A; Vogel W; Liver Int; 2003 Aug; 23(4):269-75. PubMed ID: 12895267 [TBL] [Abstract][Full Text] [Related]
16. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072 [TBL] [Abstract][Full Text] [Related]
17. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response]. Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533 [TBL] [Abstract][Full Text] [Related]
18. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders. Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735 [TBL] [Abstract][Full Text] [Related]
19. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916 [TBL] [Abstract][Full Text] [Related]
20. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response]. Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]